Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Prevention |
RCV000251683 | SCV000305255 | likely benign | not specified | criteria provided, single submitter | clinical testing | ||
Labcorp Genetics |
RCV000525190 | SCV000644662 | benign | Tuberous sclerosis 2 | 2024-12-27 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV001026217 | SCV001188555 | likely benign | Hereditary cancer-predisposing syndrome | 2017-09-27 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Gene |
RCV001640487 | SCV001858393 | benign | not provided | 2019-07-08 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV000525190 | SCV002041259 | benign | Tuberous sclerosis 2 | 2021-11-07 | criteria provided, single submitter | clinical testing | |
Sema4, |
RCV001026217 | SCV002534101 | benign | Hereditary cancer-predisposing syndrome | 2021-06-16 | criteria provided, single submitter | curation | |
Fulgent Genetics, |
RCV002479962 | SCV002795530 | likely benign | Lymphangiomyomatosis; Isolated focal cortical dysplasia type II; Tuberous sclerosis 2 | 2021-11-18 | criteria provided, single submitter | clinical testing | |
All of Us Research Program, |
RCV003998988 | SCV004817013 | benign | Tuberous sclerosis syndrome | 2023-12-01 | criteria provided, single submitter | clinical testing |